12,372 trials
Gastric Cancer
Primary: Percentage of Participants With 3-Year Progression-Free Survival (PFS), as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1 — 60.24; 66.82 percentage…
Glaucoma
Primary: Mean Difference in Intraocular Pressure (IOP) of Both Eyes Between the Two Treatment Groups at Four Time Points — 19.35; 19.75; 18.53; 18.66 mmHg
Asthma
Primary: Change From Baseline in Pre-dose FEV1 — 0.126; 0.157 Liters — p=0.214
Pulmonary Arterial Hypertension
Primary: Number of Participants That Experienced Clinical Worsening — 8; 13; 23; 14 Participants
Cocaine Dependence
Primary: Compulsion — 5.9; 5.5 score on a scale — p=<0.05
Benzodiazepine Refractory Status Epilepticus
Primary: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat — 53; 56; 68 Participants
Acute Myeloid Leukemia (AML)
Primary: Overall Survival (OS) — 4.1; 7.2 months — p=0.114
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c: Week 26 — -0.6; -1.1; -1.3; -0.8 Percentage of HbA1c — p=< 0.0001
Chronic Lymphocytic Leukemia
Primary: Participants With >/= 95 % Bruton's Tyrosine Kinase (BTK) Occupancy — 8 Participants
Osteoarthritis
Primary: Therapeutic Effect on Hemoglobin Level — 13.6; 13.6; 10.3; 9.9 g/dL
Diabetes · Diabetes Mellitus, Type 2
Primary: Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE) Composite Endpoint Consisting of: Cardiovascular Death, Non-fatal Myocardial…
Charcot-Marie-Tooth Disease Type 1A
Primary: Overall Neuropathy Limitation Scale (ONLS) Total Score — 3.33; 3.05; 3.23; 3.25 Scores on the ONLS — p=0.008
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
Pre-hypertension · JNC 7 Stage I Hypertension
Primary: Change in Systolic Blood Pressure (SBP) — -1.39; -1.06 mm Hg — p=0.83